Skip to content

Effects of BRS and LRS on Postoperative Acute Kidney Injury

Effects of Sodium Bicarbonate Ringer's Injection and Sodium Lactated Ringer's Injection on Postoperative Acute Kidney Injury in Patients Undergoing Major Abdominal Surgery: a Randomized, Controlled, Open-label Clinical Study

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04835038
Acronym
BRS/LRS
Enrollment
3400
Registered
2021-04-08
Start date
2021-06-01
Completion date
2023-08-31
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Brief summary

1. Title: Effects of Sodium Bicarbonate Ringer's Injection and Sodium Lactated Ringer's Injection on postoperative acute kidney injury in patients undergoing major abdominal surgery: a randomized, controlled, open-label clinical study 2. Objective: To evaluate the effect of BRS and LRS infusion on acute renal injury in patients undergoing major abdominal surgery 3. Primary outcome: Incidence of AKI at 28 days postoperative (defined as acute kidney injury, according to Kidgo 2012 definition and classification). 4. Study Design: Randomized, controlled, open-label clinical study.

Detailed description

1. Subjects: patients who planned to undergo elective major abdominal surgery. 2. Study data collection period: Subjects signed the consent form until 28 days after discharge or died in hospital or withdrew from the study. 3. Number of research centers/sample size: 3400 patients were planned to be included. 4. Study process: Among patients undergoing elective surgery, the researchers will include patients who meet the inclusion criteria for elective major abdominal surgery and agree to participate in the study. The data to be collected in this study will be recorded by the researcher in the eCRF, including: (1) Data to be collected during the screening period and preoperatively: patients' basic characteristics and demographic data (2) Data to be recorded during and/or after surgery: primary study indicators, secondary indicators, and other indicators.

Interventions

Intraoperative fluid therapy performed with BRS (Sodium Bicarbonate Ringer's Injection)

DRUGSodium Lactated Ringer's Injection

Intraoperative fluid therapy performed with LRS (Sodium Lactated Ringer's Injection)

Sponsors

Tongji Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. ASA grade Ⅰ-Ⅲ. 2. patients aged between 20 and 70, signed informed consent form, and are willing to participate in the study. 3. BMI ≤ 30kg/m2. 4. elective major abdominal surgery for the first time (radical resection of ovarian cancer, radical resection of cervical cancer, radical resection of gastric cancer, radical resection of colorectal cancer, radical resection of bladder tumor and radical resection of prostate tumor). 5. NYHA cardiac function grade Ⅰ-Ⅲ. 6. the function of liver and kidney is normal before operation. 7. the blood coagulation function was normal before operation. 8. hemoglobin \> 70g/L. 9. sinus rhythm was detected by electrocardiogram and there were no other malignant arrhythmias.

Exclusion criteria

1. Emergency surgery. 2. liver and kidney surgery. 3. complicated with chronic respiratory diseases and FEV1/FVC \< 70%. 4. the operation time is less than 2 hours. 5. patients with mental illness or cognitive impairment. 6. uncontrolled hypertension with blood pressure higher than 180 × 100mmHg. 7. patients with hypothyroidism. 8. pregnant or lactating patients. -

Design outcomes

Primary

MeasureTime frameDescription
Postoperative acute renal injury28 days after surgeryThe incidence of AKI at 28 days after surgery (Acute kidney injury is defined and graded according to KIDGO 2012)

Countries

China

Contacts

Primary ContactShiyong Li
shiyongli@hust.edu.cn18062154189

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026